HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
263 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
2022-05-27 (thenewsminute.com)
With Rs 5300 crore in family assets, Hetero’s Partha Saradhi Reddy to become richest MP
Hetero Group Chairman and Managing Director Bandi Partha Saradhi Reddy is all set to become India’s richest Member of Parliament with Rs 3,900 crore in assets.
Read more
(tijd.be)
Wel Jong Niet Hetero gets a new chairman
Dimitri Vanderhaeghen (31) is stepping down as chairman of the non-profit organization Wel Jong Niet Hetero (WJNH), the largest LGBT federation in our country. At the general meeting on Saturday, 25-year-old Tim Spruytte will be nominated as successor.
Read more
(exchange4media.com)
Metropolis Healthcare appoints Jeyasingh Balakrishnan as Head – PR & Corp Comm
Jeyasingh Balakrishnan has joined Metropolis Healthcare as its Head – Public Relations and Corporate Communications.
Read more
(indiatimes.com)
TRS Rajya Sabha Members: TRS names 3 candidates for Rajya Sabha polls
Hetero Drugs Chairman and Managing Director Bandi Parthasaradhi Reddy, Gayatri Group of Companies' Chief Promoter Vaviraju Ravi Chandra, and Telangana
Read more
(indiatimes.com)
GlaxoSmithKline Pharmaceuticals: GSK Pharma board approves sale of Vemgal plant to Hetero Labs, ET HealthWorld
GlaxoSmithKline Pharmaceuticals: The board of directors at its meeting held on Tuesday, approved the sale of the company's business undertaking i.e., manufacturing facility together with the land, plant and machinery, assets, software and equipment located at Vemgal, Karnataka, to Hetero Labs Ltd.
Read more
(thehindubusinessline.com)
Ranitidine recall effect: GSK sells Karnataka plant to Hetero Labs for ₹180 cr
GlaxoSmithKline Pharmaceuticals Limited (GSK) said that its board of directors has approved the sale of its manufacturing facility at Vemgal (Karnataka) to Hetero Labs Limited for ₹180 crore.
Read more